Financials

Discussions Technicals Seasonals

GEAN fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Genetic Analysis AS develops in-vitro diagnostics tests in diseases where microbiota is involved. It is a molecular diagnostic company that provides gut microbiota analysis for testing bacterial imbalance in bowel syndrome and inflammatory bowel disease patients. The company's service products include GA-map dysbiosis test and COVID-19 fecal test and lab products include The GA-map dysbiosis test reagent kit and The COVID fecal test reagent kit. Genetic Analysis was founded in 2008 and is headquartered in Oslo, Norway.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

GEAN has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company